Navigation Links
FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Date:3/17/2008

onments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.

In its current use for the treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

"The expanded clearance for the Axxent Controller is very significant in that it validates that the FDA recognizes Electronic Brachytherapy is a platform technology that is viable for treatment of conditions outside of the breast," said Michael Klein, president and CEO of Xoft. "This serves as the foundation for Xoft's expansion into new treatment areas beyond breast cancer and fuels the continued market adoption and expansion of this important technology."

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New filter clears up fiber optic communications
2. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
8. HOYA ConBio and The Hornbrook Group Announce Expanded Alliance
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
11. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
(Date:4/16/2015)... Seattle, Washington (PRWEB) April 16, 2015 ... for Applied Cancer Science and Resolution Bioscience, Inc. ... agreement to co-develop a novel, blood-based, clinic ready, ... lung cancer (NSCLC). The collaboration is the first ... ALK, RET, and ROS1 fusions in blinded plasma ...
(Date:4/16/2015)... 2015 CCI Global Channel Management, the ... planning management software for major tech and telecom vendors, ... survey of channel vendor programs in software, hardware, and ... How the top IT vendors in each segment ... coming year. , Assessment of the state ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... to the Advanced Performance of the A1 Series of ... , MELVILLE, N.Y., Dec. 15 Offering ... Nikon Instruments, Inc.,s ( www.nikoninstruments.com ) A1 series of ... software brings biological imaging to life. The software, ...
... Scientific,Corporation (NYSE: BSX ) today announced that ... Express(R) SD Renal Monorail(R),Premounted Stent System for use as ... lesions of the renal arteries. The,Express SD System ... renal arteries in the United States. It is ...
... 15 Cylene Pharmaceuticals today announced,the initiation of ... in,patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers ... "Quarfloxin (CX-3543) is a ... in the abnormal nucleoli of cancer cells, thereby,selectively ...
Cached Biology Technology:Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 2Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 4Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... and two collaborators have received a $3.4 million research ... of prostate cancer using MRI, or magnetic resonance imaging. ... two years from the American Recovery and Reinvestment Act ... of Health under an initiative to promote industry and ...
... A new internet-based tool for designing agricultural terraces ... optimize design by allowing rapid development of alternative layouts. ... Resource: Engineering & Technology for a Sustainable World , ... Engineering at the University of Missouri, introduces a web-based, ...
... species are not just discovered in exotic localeseven places ... plants and animals. Academy scientists recently named a new ... fishes distantly related to sharks, from the coast of ... the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ), ...
Cached Biology News:Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI 2Web-based innovation improves, eases agricultural terrace design 2New species of ghostshark from California and Baja California 2